Tandem Diabetes Care
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Tandem Diabetes Care sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).
Tandem Diabetes Care: 13 sponsored US clinical trials, 1 recruiting.
Tandem Diabetes Care sponsors 13 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 11 completed. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Diabetes Mellitus, Type 1, with 2 trials.
Top-decile sponsor footprint
Tandem Diabetes Care ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
11 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
13 total, page 1 of 1
Feasibility Study of Extended Wear Insulin Infusion Set Options During Home Use in People With Type 1 Diabetes
NCT07325461
PS230005 Control-IQ 1.5 Post-Approval Study
NCT06717451
Investigational Extended Wear Insulin Infusion Set in People With Type 1 Diabetes
NCT06273124
A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes
NCT05785832
Use of Control-IQ Technology 2.0 in Adults, Children, and Preschoolers With Type 1 Diabetes
NCT05683392
Safety Evaluation of an Advanced Hybrid Closed Loop System Using Lyumjev With the Tandem t:Slim X2 Insulin Pump With Control-IQ Technology in Adults, Adolescents and Children With Type 1 Diabetes
NCT05403502
Control-IQ Technology for High Insulin Users With Type 1 Diabetes (Higher-IQ)
NCT05422053
Adaptation of Insulin Delivery Settings to Improve Clinical Outcomes With AID Use
NCT05204134
Control-IQ Technology in Individuals With Type 2 Diabetes
NCT05111301
Control-IQ Technology 2.0 Adult and Adolescent Feasibility Study
NCT05014789
Control-IQ Observational (CLIO) Post-Approval Study
NCT04503174
Diabetes Pump With Predictive Low Glucose Suspend Pivotal Trial
NCT03195140
Tandem Predictive Low Glucose Suspend Inpatient Feasibility Study
NCT02877771
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
Therapeutic Areas
What is open in the Tandem Diabetes Care pipeline
1 recruiting of 13 indexed (8% open); 11 completed (85%).
Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).
Top condition: Diabetes Mellitus, Type 1 (2 trials), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Tandem Diabetes Care: open-pipeline peers nationwide
Peers matched on 13 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
Tandem Diabetes Care sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 13 trials (± recruiting share)
- Adaptimmune · 13 trials · 0% recruiting
- Agennix · 13 trials · 0% recruiting
- Akili Interactive Labs · 13 trials · 0% recruiting
- Alumis · 13 trials · 8% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Andrei Iagaru · 8% recruiting · 13 trials
- BioXcel Therapeutics · 8% recruiting · 13 trials
- Corporal Michael J. Crescenz VA Medical Center · 8% recruiting · 13 trials
- Fresenius Medical Care North America · 8% recruiting · 13 trials
Related
What to do with this Tandem Diabetes Care page
13 registered trials is a research-attention snapshot, not an endorsement of Tandem Diabetes Care or any single study.
- 1 of Tandem Diabetes Care's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Diabetes Mellitus, Type 1 is the condition Tandem Diabetes Care studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Diabetes Mellitus, Type 1 trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Tandem Diabetes Care pipeline card: 13 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.